Regeneron’s one-dose cocktail prevents Covid risk for up to 8 months

16

Washington, Nov 9 | A single shot of Regeneron Pharmaceuticals’s antibody cocktail reduced the risk of Covid-19 by 81.6 per cent for two to eight months, according to results of the phase-3 trials presented by the company.

Casirivimab and Imdevimab injection is a cocktail of two monoclonal antibodies and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes Covid-19. The monoclonal antibodies are produced by recombinant DNA technology.

During the eight-month assessment period there were zero hospitalisations for Covid-19 and deaths in the REGEN-COV group, but six such incidents were recorded in the placebo group, the company said.

“These results demonstrate that REGEN-COV has the potential to provide long-lasting immunity from SARS-CoV-2 infection,” said Myron S. Cohen, who leads monoclonal antibody efforts for the US National Institutes of Health-sponsored Covid Prevention Network.

The findings are particularly important to those who do not respond to Covid-19 vaccines including people who are immunocompromised, the company said.

The therapy had previously shown an 81.4 per cent risk reduction during the first month after administration.

Besides providing long-term protection against Covid-19, the trial also showed that the drug cocktail prevented “including times of particularly high risk from household exposure”, the company said.

REGEN-COV has not been approved by the FDA, but is currently authorised in the US for the treatment and post-exposure prophylaxis in certain high risk individuals.

To increase global supply of the antibody cocktail, Regeneron has collaborated with Roche including in India.

Emergency or temporary pandemic use authorisations are currently in place in more than 40 countries, including India, the US, Switzerland and Canada, while the antibody cocktail is fully approved in Japan and conditionally approved in the UK.

Source: IANS

Next Story

Weekly Technical Share Market Outlook

Weekly Technical Share Market Outlook

The Indian market recovered sharply on the last trading day amid the weekend after a continuous fall. Market has managed to halt above 16000 Nifty levels after continuous losing streak. Index reacted violently, grasping Indian as well as global factors throughout the week. Simultaneously, Inflation is catching up and profit margins are taking a hit.

 

Sensex advanced 1532 points or 2.90 percent while Nifty gained 484 points or 3.07 percent in a week. Simultaneously, Bank nifty has overcome bear’s dominance ending the session with 3.49 percent gain. Sectorally,Nifty Metal saw the highest gains of 7.40 percent followed by the Realty and Auto added over 4% gain. On the flip side Nifty IT tumbled 2.82 percent on weekly basis. Midcap and Small Cap measures rising nearly 2 percent as well.

In Nifty stock, EICHERMOT gained 11.31% while TECHM lost 5.98% on a weekly basis. INDIA VIX closes at 23.10 suggests volatility driven market is going to remain intact. Coming to the OI Data, on the call side highest OI witnessed at 17000 Nifty followed by 16800 Nifty strike price while on the put side, the highest OI was at 16000 Nifty followed by 15800 Nifty strike price. Technically, Nifty has formed a Tweezer Bottom type pattern in the weekly chart suggesting a short term buying rally may drive the market until monthly expiry. On the daily chart, price has rebounded from the lower Bollinger band as well.

Momentum indicators MACD & Stochastic were trading with a positive crossover & reversed from oversold zone. However, Index is still struggling to get the support of 50 Simple Moving Average in daily chart. Short term investors and traders are advised to work with option strategies to neutralize the volatility. Overall, Nifty is having support at 15700 mark while on the upside 16700 followed by 16500 may act as an immediate resistance. While Bank nifty has support around 32500 while resistance is placed at 36000 on weekly chart.

Sumeet Bagadia
Executive Director
Choice Broking

Source: Choice India

LEAVE A REPLY

Please enter your comment!
Please enter your name here